Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL359549 | 1.00 | HPGD (0.44) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL25741844 | 1.00 | HPGD (0.44) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL31040999 | 0.95 | HPGD (0.47) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30922845 | 0.95 | HPGD (0.47) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL358661 | 0.90 | USP2 (0.46) | HPGDUSP2SMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL15797058 | 0.90 | USP2 (0.46) | HPGDUSP2SMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL17163075 | 0.90 | USP2 (0.46) | HPGDUSP2SMN1; SMN2EPHX1ALDH1A1 | |
| SCHEMBL21855997 | 0.87 | HPGD (0.48) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12683369 | 0.85 | HPGD (0.47) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL21145481 | 0.84 | HPGD (0.55) | HPGDUSP2SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-07-24 | — | — | US | disclosed |
| US-20240294551-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2024-09-05 | — | — | US | disclosed |
| WO-2024107686-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2024-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | HPGD 1367/4885USP2 3635/4885SMN1; SMN2 3059/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | HPGD 2567/4885USP2 3246/4885SMN1; SMN2 1780/4885 |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | HPGD 1367/4885USP2 3635/4885SMN1; SMN2 3059/4885 |
| US-20240294551-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | HPGD 1367/4885USP2 3635/4885SMN1; SMN2 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.